| 1 |
33723657 | Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors? | 2021 Sep |
1 |
| 2 |
31535851 | Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples. | 2020 Jan 21 |
2 |
| 3 |
31932871 | Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. | 2020 Apr |
1 |
| 4 |
30367352 | Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. | 2019 May |
3 |
| 5 |
29440451 | Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. | 2018 May |
1 |
| 6 |
29464464 | Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report. | 2018 Jun |
1 |
| 7 |
25737032 | Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking. | 2016 Aug |
7 |
| 8 |
24800949 | Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. | 2014 May 27 |
1 |
| 9 |
23636448 | Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. | 2013 Jun |
3 |
| 10 |
25819130 | [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. | 2011 |
1 |
| 11 |
20881954 | An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. | 2010 Nov |
1 |